43.29
-0.38 (-0.87%)
| Previous Close | 43.67 |
| Open | 43.97 |
| Volume | 32,870 |
| Avg. Volume (3M) | 140,932 |
| Market Cap | 405,551,968 |
| Price / Book | 2.15 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2024 |
| Diluted EPS (TTM) | -9.42 |
| Total Debt/Equity (MRQ) | 23.26% |
| Current Ratio (MRQ) | 11.23 |
| Operating Cash Flow (TTM) | -73.69 M |
| Levered Free Cash Flow (TTM) | -81.13 M |
| Return on Assets (TTM) | -35.27% |
| Return on Equity (TTM) | -74.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Korro Bio, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.44% |
| % Held by Institutions | 91.36% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Qiming U.S. Ventures Management, Llc | 30 Sep 2024 | 368,085 |
| 72 Investment Holdings, Llc | 30 Sep 2024 | 276,831 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 153.00 (Raymond James, 253.43%) | Buy |
| Median | 122.50 (182.98%) | |
| Low | 105.00 (RBC Capital, 142.55%) | Buy |
| Average | 125.75 (190.48%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 62.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Nov 2024 | 115.00 (165.65%) | Buy | 52.31 |
| 13 Nov 2024 | 115.00 (165.65%) | Buy | 55.01 | |
| Jones Trading | 18 Nov 2024 | 130.00 (200.30%) | Buy | 46.63 |
| RBC Capital | 21 Oct 2024 | 105.00 (142.55%) | Buy | 75.86 |
| Raymond James | 21 Oct 2024 | 153.00 (253.43%) | Buy | 75.86 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Nov 2024 | Announcement | Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency |
| 21 Nov 2024 | Announcement | Korro to Participate in Upcoming Investor Conferences |
| 14 Nov 2024 | Announcement | Korro to Present at the Jefferies London Healthcare Conference |
| 12 Nov 2024 | Announcement | Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates |
| 04 Nov 2024 | Announcement | Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board |
| 30 Sep 2024 | Announcement | Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |